PVI
KROS icon

Pura Vida Investments’s Keros Therapeutics KROS Stock Holding History

Pura Vida Investments’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,000
Closed -$353K – 238
2020
Q4 		$353K Buy
+5,000
New +$315K 0.01% 171

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Pura Vida Investments's KROS Position: Q1 2021 in Review

Pura Vida Investments sold out of Keros Therapeutics (KROS) in Q1 2021, closing a stake of 5,000 shares — an estimated $353K sold.

Pura Vida Investments first reported a position in KROS in Q4 2020 and held it in 1 quarter. The position peaked at $353K in Q4 2020. 83 funds tracked by Wall St. Rank hold KROS as of Q1 2021.

  • Pura Vida Investments reported no remaining Keros Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Pura Vida Investments sold 5,000 Keros Therapeutics shares in Q1 2021, an estimated $353K.
  • Pura Vida Investments first reported a position in Keros Therapeutics in Q4 2020 and held it in 1 quarter.
  • Pura Vida Investments's Keros Therapeutics position peaked at $353K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2021.

Based on Pura Vida Investments's 13F filing for Q1 2021, filed 12 May 2021.